de Vries EGE - Search Results

1

⁸⁹Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted ²²⁷Th-Conjugate Therapy in Mice.

Broer LN, Knapen DG, Suurs FV, Moen I, Giesen D, Waaijer SJH, Indrevoll B, Ellingsen C, Kristian A, Cuthbertson AS, de Groot DA, Cole PE, de Vries EGE, Hagemann UB, Lub-de Hooge MN. Broer LN, et al. Among authors: de vries ege, de groot da. J Nucl Med. 2022 Nov;63(11):1715-1721. doi: 10.2967/jnumed.121.263079. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422447 Free article.

2

Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism.

Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH. Meijer WG, et al. J Nucl Med. 2003 Feb;44(2):184-91. J Nucl Med. 2003. PMID: 12571207 Free article.

3

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Lub-de Hooge MN, et al. Br J Pharmacol. 2004 Sep;143(1):99-106. doi: 10.1038/sj.bjp.0705915. Epub 2004 Aug 2. Br J Pharmacol. 2004. PMID: 15289297 Free PMC article.

4

Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.

Koopmans KP, Brouwers AH, De Hooge MN, Van der Horst-Schrivers AN, Kema IP, Wolffenbuttel BH, De Vries EG, Jager PL. Koopmans KP, et al. J Nucl Med. 2005 Jul;46(7):1240-3. J Nucl Med. 2005. PMID: 16000294 Free article.

5

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG. Perik PJ, et al. J Clin Oncol. 2006 May 20;24(15):2276-82. doi: 10.1200/JCO.2005.03.8448. J Clin Oncol. 2006. PMID: 16710024

6

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. Nagengast WB, et al. J Nucl Med. 2007 Aug;48(8):1313-9. doi: 10.2967/jnumed.107.041301. Epub 2007 Jul 13. J Nucl Med. 2007. PMID: 17631557 Free article.

7

Immuno-PET: a navigator in monoclonal antibody development and applications.

van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. van Dongen GA, et al. Oncologist. 2007 Dec;12(12):1379-89. doi: 10.1634/theoncologist.12-12-1379. Oncologist. 2007. PMID: 18165614 Free article. Review.

8

18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.

Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP. Koopmans KP, et al. J Nucl Med. 2008 Apr;49(4):524-31. doi: 10.2967/jnumed.107.047720. J Nucl Med. 2008. PMID: 18375923 Free article.

9

Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy.

Dijkers EC, de Vries EG, Kosterink JG, Brouwers AH, Lub-de Hooge MN. Dijkers EC, et al. Curr Pharm Des. 2008;14(31):3348-62. doi: 10.2174/138161208786549425. Curr Pharm Des. 2008. PMID: 19075712 Review.

10

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.

Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S. Duiker EW, et al. Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276284 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

552 results

Search Page